N@N

Inside the futuristic biotech startup Cellares that's building a cure for cancer with $355 million in funding

Cellares, a biotech startup, has raised $255 million in Series C funding, bringing its total funding to $355 million, to revolutionize cancer treatment through automation. The company is developing the Cell Shuttle, an automated manufacturing platform designed to produce cell therapies at scale, aiming to reduce costs and increase accessibility. This platform automates the entire process from cell thawing to final product formulation, potentially allowing for the production of therapies in just a few days compared to weeks or months in traditional methods. Cellares' approach not only promises to make cell therapies more affordable but also aims to standardize the production process, which could lead to more consistent and reliable treatments. The funding will help expand their operations, including building a new manufacturing facility in Bridgewater, New Jersey, and scaling up their technology to meet the growing demand for personalized cancer treatments.

Read the Full Fortune Article at:
[ https://www.msn.com/en-us/money/companies/inside-the-futuristic-biotech-startup-cellares-that-s-building-a-cure-for-cancer-with-355-million-in-funding/ar-AA1BxAz9 ]